J Korean Med Sci.  2012 Apr;27(4):458-459. 10.3346/jkms.2012.27.4.458.

Reversible Dysphasia and Statins

• Davies GR

• KMID: 2157911
• DOI: http://doi.org/10.3346/jkms.2012.27.4.458

Abstract

This paper presents a case of reversible dysphasia occurring in a patient prescribed atorvastatin in combination with indapamide. A milder dysphasia recurred with the prescription of rosuvastatin and was documented on clinical examination. This resolved following cessation of rosuvastatin. The case highlights both a need for a wider understanding of potential drug interactions through the CYP 450 system and for an increased awareness, questioning and reporting of drug side-effects.

Keyword

Dysphasia; Statins; Drug Interactions

MeSH Terms

Anticholesteremic Agents/adverse effects/*therapeutic use
Antihypertensive Agents/therapeutic use
Anxiety/diagnosis
Aphasia/diagnosis/*etiology
Cytochrome P-450 Enzyme System/metabolism
Depression/diagnosis
Drug Interactions
Female
Fluorobenzenes/adverse effects/*therapeutic use
Heptanoic Acids/adverse effects/*therapeutic use
Humans
Hypercholesterolemia/drug therapy
Indapamide/therapeutic use
Middle Aged
Pyrimidines/adverse effects/*therapeutic use
Pyrroles/adverse effects/*therapeutic use
Sulfonamides/adverse effects/*therapeutic use

Reference

1. Roberts WC. It's the cholesterol, stupid! Am J Cardiol. 2010. 106:1364–1366.

2. Wagstaff LR, Mitton MW, Arvik BM, Doraiswamy PM. Statin-associated memory loss: analysis of 60 case reports and review of the literature. Pharmacotherapy. 2003. 23:871–880.

3. Parale GP, Baheti NN, Kulkarni PM, Panchal NV. Effects of atorvastatin on higher functions. Eur J Clin Pharmacol. 2006. 62:259–265.

4. Chariot P, Abadia R, Agnus D, Danan C, Charpentier C, Gherardi RK. Simvastin-induced rhabdomyolisis followed by a MELAS syndrome. Am J Med. 1993. 94:109–110.

5. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janacek E, Domecq C, Greenblatt DJ. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981. 30:239–245.

6. Bellosta S, Paoletti R, Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation. 2004. 109:III50–III57.

7. Sun H, Moore C, Dansette PM, Kumar S, Halpert JR, Yost GS. Dehydrogenation of the indoline-containing rug, 4-chloro-N-(2-methyl-1-indolinyl) 3-sulfamoylbenzamide (indapamide), by CYP3A4: correlation with in silico predictions. Drug Metab Dispos. 2009. 37:672–684.

8. Ihara Y, Namba R, Kuroda S, Sato T, Shirabe T. Mitochondrial encephalomyopathy (MELAS): pathological study and successful therapy with coenzyme Q10 and idebenone. J Neurol Sci. 1989. 90:263–271.

9. Baker SK, Tarnopolsky MA. Statin myopathies: pathophysiologic and clinical perspectives. Clin Invest Med. 2001. 24:258–272.

10. Vladutiu GD, Simons Z, Isackson PJ, Tarnopolsky M, Peltier WL, Barboi AC, Sripathi SN, Wortmann RL, Phillips PS. Genetic risk factors associated with lipid-lowering drug-unduced myopathies. Muscle Nerve. 2006. 34:153–162.

11. Oh J, Ban MR, Miskie BA, Pollex RL, Hegele RA. Genetic determinants of statin intolerance. Lipids Health Dis. 2007. 6:7.

12. Accad M. More reasons statin drugs are shunned. Am J Cardiol. 2011. 107:957.

13. Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, Carrasquillo MM, Abraham R, Hamshere ML, Pahwa JS, Moskvina V, et al. Common variants in ABCA7, MS46A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimers disease. Nat Genet. 2011. 43:429–435.